Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609398 | PMC |
| http://dx.doi.org/10.1002/ams2.70028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Innovative application of the Versius Surgical System® in subtotal colectomy for refractory slow-transit constipation: A video vignette.
Colorectal Dis
February 2025
Department of Surgery, Hospital Sant' Antonio, University of Padova, Padua, Italy.
Targeting Janus kinase 1 in refractory Behçet's disease: a case report on the clinical efficacy of upadacitinib.
Intern Emerg Med
January 2025
Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy.
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Biomark Res
January 2025
Incyte Corporation, Wilmington, DE, USA.
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treatment in adults ineligible for autologous stem cell transplantation. This retrospective analysis examined characteristics and outcomes of adults with R/R DLBCL who received tafasitamab preceding CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in a real-world setting.
View Article and Find Full Text PDFTreatment with infliximab and tacrolimus in steroid-refractory pneumonitis secondary to anti-HER2 therapy.
ESMO Open
January 2025
The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. Electronic address:
CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion Trial.
Am J Hematol
January 2025
Department of Hematology, Beijing Chao-Yang Hospital Capital Medical University, Beijing, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!